Overview

Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma

Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This research study is studying Dasatinib as a possible treatment for cancer of bile ducts.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Bristol-Myers Squibb
TargetCancer Foundation
Treatments:
Dasatinib